A Phase 1 Non- Randomized Open Label Sequential Group Multicenter Study To Evaluate The Antiviral Activity Of Multiple Doses Of A Small Molecule Direct Antiviral Agent In Chronically Infected Hepatitis C Subjects.

Trial Profile

A Phase 1 Non- Randomized Open Label Sequential Group Multicenter Study To Evaluate The Antiviral Activity Of Multiple Doses Of A Small Molecule Direct Antiviral Agent In Chronically Infected Hepatitis C Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2014

At a glance

  • Drugs Filibuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 18 Apr 2011 Results reported in Hepatology.
    • 13 Jan 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 13 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top